ORMP
ORAMED PHARMACEUTICALS INC.ORAMED PHARMACEUTICALS INC. reported revenue of $2.00M in its most recent fiscal year. It kept 3202.5% of that as net income, and generated -$9.15M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | Not reported | 7.4% | — |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -9.6% | 7.6% | 142 / 186 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | -5.9% | 7.3% | 129 / 169 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -33.3% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 4.0% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | 21.8% | 3.8% | 3 / 29 |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -7.9% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 0.7% | 72.1% | 113 / 116 |
Operating margin Operating income as a share of revenue. | -754.4% | -34.2% | 157 / 163 |
Net margin Net income as a share of revenue. | 3202.5% | -30.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | -457.7% | -15.3% | 136 / 156 |
Return on equity Net income divided by shareholder equity. | 32.1% | -52.3% | 15 / 368 |
Return on assets Net income divided by total assets. | 27.7% | -37.6% | 9 / 419 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -8.3% | -49.3% | 53 / 257 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.24x | — |
Current ratio Current assets over current liabilities. | 6.98x | 4.17x | 134 / 419 |
Quick ratio Current assets excluding inventory, over current liabilities. | 6.98x | 3.84x | 133 / 419 |
Interest coverage Operating income divided by interest expense. | Not reported | -15.21x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.56x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Dividend record
What the dividend has actually done, not a prediction of what it will do. Changes are checked against total dollars paid so that stock splits are not mistaken for cuts.
Dividend history is limited to what companies have filed in machine-readable form, which generally begins around 2009. A company may have paid or raised its dividend for far longer than shown here.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 24 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Hexter Joshua COO & CBO | Open-market sale | 30,000 | $4.51 | $135.3K |
| Oct 1, 2026 | Gabay Avraham Chief Financial Officer | Open-market sale | 20,000 | $4.51 | $90.2K |
| Sep 24, 2026 | Gabay Avraham Chief Financial Officer | Grant or award | 209,291 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Grant or award | 208,125 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Grant or award | 209,291 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 104,000 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 100,000 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 69,999 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 47,000 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 100,000 | — | — |
| Sep 24, 2026 | Kidron Miriam Chief Scientific Officer | Returned to company(derivative) | 72,000 | — | — |
| Sep 24, 2026 | Hexter Joshua COO & CBO | Grant or award | 75,455 | — | — |
| Sep 24, 2026 | Hexter Joshua COO & CBO | Grant or award | 209,291 | — | — |
| Sep 24, 2026 | Hexter Joshua COO & CBO | Returned to company(derivative) | 50,000 | — | — |
| Sep 24, 2026 | Hexter Joshua COO & CBO | Returned to company(derivative) | 50,000 | — | — |
| Sep 24, 2026 | Hexter Joshua COO & CBO | Returned to company(derivative) | 36,000 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Grant or award | 349,497 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Grant or award | 368,765 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 196,500 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 190,000 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 49,000 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 97,000 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 150,000 | — | — |
| Sep 24, 2026 | KIDRON NADAV President and CEO | Returned to company(derivative) | 107,000 | — | — |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | — | $1.34M | $2.70M | $2.70M | $2.71M | $2.70M | $2.45M | $2.46M | $641.0K |
| Gross profit | $13.0K | — | — | — | — | — | — | — | — | — |
| Operating income | -$15.09M | -$12.78M | -$15.77M | -$40.60M | -$24.22M | -$11.76M | -$14.63M | -$13.53M | -$10.77M | -$10.01M |
| Net income | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.99M | -$11.51M | -$14.36M | -$12.73M | -$10.48M | -$10.96M |
| EPS (diluted) | $1.50 | -$0.48 | $0.14 | -$0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 |
| Operating cash flow | -$9.14M | -$8.41M | -$10.29M | -$27.92M | -$21.18M | -$12.44M | -$12.94M | -$14.66M | -$5.83M | $4.66M |
| Capital expenditure | $9.0K | $18.0K | $254.0K | $496.0K | $375.0K | $82.0K | $15.0K | $5.0K | $7.0K | $9.0K |
| Free cash flow | -$9.15M | -$8.43M | -$10.55M | -$28.41M | -$21.56M | -$12.52M | -$12.96M | -$14.66M | -$5.84M | $4.65M |
| Total assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M | $44.63M | $34.66M | $47.40M | $38.71M | $42.83M |
| Shareholder equity | $199.74M | $146.26M | $163.82M | $151.81M | $115.77M | $32.88M | $19.39M | $31.11M | $19.24M | $26.19M |
| Total debt | — | — | $51.01M | $25.0K | $12.54M | — | $12.36M | $13.84M | — | — |
| Cash | $45.95M | $54.42M | $9.05M | $40.46M | $77.25M | $19.30M | $3.33M | $5.00M | $3.97M | $3.91M |
| Dividends per share | $0.25 | — | — | — | — | — | — | — | — | — |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from ORAMED PHARMACEUTICALS INC.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 26, 2026. View filings on EDGAR.